Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00632450 · ClinicalTrials.gov registry record
EnSite Real-Time Cardiac Performance Measurements (RT CPM) Study
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 21
- Enrollment target
NCT00632450: Completed study, sponsored by Abbott Medical Devices.
NCT00632450 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00632450 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
The EnSite Real-Time Cardiac Performance Measurements Study (EnSite RT CPM) is a multicenter, international, acute, non-significant risk study, designed to enroll a maximum of 40 patient. The goal of the study is to collect 3-D systolic/diastolic data with the EnSite NavX Mapping system during a CRT implant. Patients enrolled in this study will undergo NavX CPM recording of the heart using the EnSite NavX Mapping system during the implantation of a cardiac resynchronization therapy device.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-10 |
What the finished NCT00632450 record still lists
NCT00632450 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00632450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00632450 about?
NCT00632450 is a clinical study titled "EnSite Real-Time Cardiac Performance Measurements (RT CPM) Study". The EnSite Real-Time Cardiac Performance Measurements Study (EnSite RT CPM) is a multicenter, international, acute, non-significant risk study, designed to enroll a maximum of 40 patient. The goal of the study is to collect 3-D systolic/diastolic data with the EnSite NavX Mapping system during a CRT...
What is the current status of trial NCT00632450?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2007-12. Estimated completion is 2008-10.
Who is sponsoring clinical trial NCT00632450?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia